Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 14 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 6032
Sealed predictions
- DYNC1LI1 in dopamine neurons, braak-0.31 (p 0.414) → +0.27 (p 0.489)receipt 6039
Swarm cases
receipt 6039: DYNC1LI1 in dopamine neurons, braak
- power
- full sample +0.00 (p 0.997, n 18), 95% CI -0.47 to +0.47. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.01 (p 0.983, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.17 (p 0.504, n 18). could be the mix.
- skeptic
- leave-one-out range -0.10 to +0.10, sign flips 11; without severely affected donors +0.00 (p 0.997, n 18). fragile.
- cell type
- strongest in microglia: +0.64 (p 0.0039, n 18) vs +0.00 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DYNC1LI1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up DYNC1LI1 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.13 p 0.657 (needs p < 3.3e-4)
Receipts
loading the receipts